enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Papillary urothelial neoplasm of low malignant potential

   en.wikipedia.org/wiki/Papillary_urothelial...

   They cannot be reliably differentiated from low grade papillary urothelial carcinomas using cytology, [1] and their diagnosis (vis-a-vis low grade papillary urothelial carcinoma) has a poor inter-rater reliability. [2] Pathologic grading and staging tumors are: graded by the degree of cellular atypia (G1->G3), and staged: [citation needed ...

3. Bladder cancer - Wikipedia

   en.wikipedia.org/wiki/Bladder_cancer

   Severe bladder tumors often shed cells into the urine; these can be detected by urine cytology, where cells are collected from a urine sample, and viewed under a microscope. [6] [7] Cytology can detect around two thirds of high-grade tumors, but detects just 1 in 8 low-grade tumors. [8]

4. Transitional cell carcinoma - Wikipedia

   en.wikipedia.org/wiki/Transitional_cell_carcinoma

   It accounts for 95% of bladder cancer cases and bladder cancer is in the top 10 most common malignancy disease in the world and is associated with approximately 200,000 deaths per year in the US. [2] [3] It is the second most common type of kidney cancer, but accounts for only five to 10 percent of all primary renal malignant tumors. [4]

5. Pfizer's bladder cancer therapy meets main goal in late-stage ...

   www.aol.com/news/pfizers-bladder-cancer-therapy...

   The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...

6. FDA approves bladder cancer treatment by Culver City company

   www.aol.com/news/fda-approves-bladder-cancer...

   For premium support please call: 800-290-4726 more ways to reach us

7. Nadofaragene firadenovec - Wikipedia

   en.wikipedia.org/wiki/Nadofaragene_firadenovec

   The safety and effectiveness of nadofaragene firadenovec was evaluated in a multicenter clinical study (Study CS-003 (NCT02773849)) that included 157 participants with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer, 98 of whom had BCG-unresponsive carcinoma in situ with or without papillary tumors and could be evaluated for response.